Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
The IMID Forum
00:00
Intro
Results from a phase 3 trial on Upadacitinib and certolizumab pegol in non-radiographic axial spondyloarthritis are compared, particularly looking at clinical outcomes and stratification by baseline MRI and CRP status.
Transcript
Play full episode
